Follow-up study for an mRNA vaccine given before
Part of Genetic & congenital, Hormones & metabolism clinical trials.
This is a follow-up study for people who already received the mRNA-3927 vaccine in an earlier trial. It looks at how safe the treatment is over the long term and whether it continues to have benefit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You already joined the earlier mRNA-3927-P101 study.
- You completed the end-of-treatment/end-of-study visit in mRNA-3927-P101.
- You will get your first dose in this follow-up study within about 11–17 days after your last mRNA-3927 dose in the earlier study.
- Your study doctor needs to think you could reasonably benefit from continuing mRNA-3927.
- You must not have any serious medical issue or lab result that the study doctor feels would make participation too risky.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an mRNA medicine (mRNA-3927) in people with propionic acidemia (PA). It aims to see whether this treatment is safe and can help the body when PA is confirmed by genetic testing.
This study follows people with propionic acidemia to better understand how the body, diet, gut bacteria, and blood chemistry change over time. It may help researchers learn more about the condition and how pregnancy, transplant, and daily life affect health.
This trial tests a new gene therapy treatment designed to help the body process certain amino acids better in infants with propionic acidemia. The therapy uses a modified virus to deliver a working copy of a faulty gene, potentially reducing dangerous acid buildups and hospital visits.
This is a “chart review” study that looks at how people with propionic acidemia have symptoms and medical events over time. It uses existing medical records (not an experimental drug) to better understand the disease and care needs.
This is a follow-up study that checks the long-term safety and health benefits of mRNA-3705 for people who took it in an earlier trial (or had to pause dosing due to COVID-19 vaccination). You may be invited if you completed the earlier study schedule or can transition early because you missed several doses.
This study tests a new type of COVID-19 vaccine that is designed to train your immune system to make stronger, longer-lasting protection. You may be able to join if you are 40–64, have already had at least two doses of a mRNA COVID-19 vaccine (Pfizer or Moderna) more than 4 months ago, and are generally healthy.
Hear when a new Propionic Acidemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.